In our study, we developed a radiomics nomogram based on 18F-FDG PET/CT radiomics features combined with clinicopathological factors to predict survival outcomes in patients with lung adenocarcinoma of EGFR mutations, with the aim of providing guidance for personalized targeted treatment of patients with lung adenocarcinoma with EGFR mutations. This evidence concerns the gene EGFR and lung adenocarcinoma.